NCT01437878 - Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2012

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Chronic Obstructive Pulmonary DiseasePulmonary Hypertension

Interventions

DRUG

Iloprost

5ug dose of inhaled iloprost (20ug/mL solution) administered 6 to 9 times per day for 4 weeks

DRUG

Placebo

matching placebo

Trial Locations (11)

University of Pittsburgh Medical Center, Pittsburgh

Temple University Hospital, Philadelphia

Mayo Clinic Jacksonville, Jacksonville

Cleveland Clinic, Cleveland

Hopital d'adultes de Brabois, Vandœuvre-lès-Nancy

Northwestern University, Chicago

Ochsner Clinic Foundation, New Orleans

University of Oklahoma Health Sciences Center, Oklahoma City

Los Angeles Biomedical Research Institute, Torrance

Massachusetts General Hospital, Boston

Hospital Clinic i Provincial, Barcelona